M 18
Alternative Names: M-18Latest Information Update: 13 Oct 2006
Price :
$50 *
At a glance
- Originator Kyowa Hakko
- Class Antineoplastics
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Oct 2006 Discontinued - Preclinical for Cancer in Japan (unspecified route)
- 05 Aug 1998 No-Development-Reported for Cancer in Japan (Unknown route)
- 21 Mar 1996 Preclinical development for Cancer in Japan (Unknown route)